Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2015 | Importance of Bcl-2-targeted therapies

John Gribben and Stephan Stilgenbauer • 4 Dec 2015

ASH 2015

Chronic Lymphocytic Leukemia Venetoclax

At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the importance of Bcl-2-targeted therapies. They discuss recent successes of Bcl-2 targeting drugs, such as venetoclax (ABT-196) in the field of chronic lymphocytic leukemia.

Investigating the treatment preferences of physicians in R/R follicular lymphoma

John Gribben • 9 Dec 2023

Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort

John Gribben • 9 Dec 2023

The future of CLL therapy

John Gribben • 9 Dec 2023

Novel therapies in NHL: antibody-drug conjugates

Andrew Davies et al. • 17 Oct 2023

Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials

Stephan Stilgenbauer • 11 Dec 2023

Acquired mutations associated with resistance to BTKi in patients with CLL

Stephan Stilgenbauer • 11 Dec 2023

Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12

Stephan Stilgenbauer • 11 Dec 2023

Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL

Stephan Stilgenbauer • 11 Dec 2023

Related Videos

EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation

Valentin Ortiz-Maldonado • 16 Apr 2024

A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies

Pau Abrisqueta • 5 Apr 2024

Early detection and interception across hematological cancers

Irene Ghobrial • 8 Apr 2024

Monoclonal B-cell lymphocytosis: a disease to be (or not to be)

Paolo Ghia • 7 Apr 2024